TCR2 Therapeutics Inc. (NASDAQ: TCRR) Stock: Looks Like An Option To Consider

[view original post]

TCR2 Therapeutics Inc. (NASDAQ:TCRR) price on Friday, December 10, fall -4.80% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $4.96.

A look at the stock’s price movement, the close in the last trading session was $5.21, moving within a range at $4.89 and $5.26. The beta value (5-Year monthly) was 2.09. Turning to its 52-week performance, $35.86 and $4.77 were the 52-week high and 52-week low respectively. Overall, TCRR moved -28.74% over the past month.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


TCR2 Therapeutics Inc.’s market cap currently stands at around $197.90 million, with investors looking forward to this quarter’s earnings report slated for Aug 10, 2021 – Aug 16, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.65, which has seen fiscal year 2021 EPS growth forecast to increase to -$2.6 and about -$3.03 for fiscal year 2022. Per the data, EPS growth is expected to be -8.30% for 2021 and -16.50% for the next financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that TCRR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 8 recommend TCRR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

TCRR’s current price about -13.26% and -26.34% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 28.63, while 7-day volatility ratio is 6.96% and 6.67% in the 30-day chart. Further, TCR2 Therapeutics Inc. (TCRR) has a beta value of 0, and an average true range (ATR) of 0.36. Analysts have given the company’s stock an average 52-week price target of $24.90, forecast between a low of $7.00 and high of $42.00. Looking at the price targets, the low is -41.13% off current price level while to achieve the yearly target high, price needs to move -746.77%. Nonetheless, investors will most likely welcome a -414.11% jump to $25.50 which is the analysts’ median price.

In the market, a comparison of TCR2 Therapeutics Inc. (TCRR) and its peers suggest the former has performed considerably weaker. Data shows TCRR’s intraday price has changed -4.80% in last session and -84.42% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.95% and 0.60% respectively in the last trading.

If we refocus on TCR2 Therapeutics Inc. (NASDAQ:TCRR), historical trading data shows that trading volumes averaged 0.9 million over the past 10 days and 911.44K over the past 3 months. The company’s latest data on shares outstanding shows there are 38.20 million shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

The 1.29% of TCR2 Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 88.00% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.72 million on Aug 12, 2021, giving us a short ratio of 8.29. The data shows that as of Aug 12, 2021 short interest in TCR2 Therapeutics Inc. (TCRR) stood at 7.13% of shares outstanding, with shares short rising to 2.45 million registered in Jul 14, 2021. Current price change has pushed the stock -83.96% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TCRR stock continues to rise going into the next quarter.